D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Recruiting

PHASE3Ages 18+InterventionalTreatment

InnoPharmax Inc.

~240 participants

Updated 2026-07-30 on ClinicalTrials.gov

What's tested:D07001-Softgel CapsulesPlaceboCapecitabine

At a glance

Recruiting sites

3 of 4 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Overall Survival (OS)

Measured over From date of randomization until the date of death, assessed up to 2 years

Biliary Tract Cancer (BTC)

NCT06622057

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwanstudy coordinator listed
Not yet recruiting
Mount Sinai Medical Center
Miami Beach, Floridastudy coordinator listed
Recruiting
The University of Arizona Cancer Center
Tucson, Arizonastudy coordinator listed
Recruiting
University Hospital Cleveland Medical Center
Cleveland, Ohiostudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Yuyuan Lin

Opens a ready-to-send draft in your own email app — review before sending.

Overall Survival (OS)From date of randomization until the date of death, assessed up to 2 years
To assess the over survival (OS) of 2 doses of D07001-softgel capsules + capecitabine compared with placebo + capecitabine